Appendix 4E, Full Year Statutory Accounts & Annual Report

Key points

• Revenue increased by 42% to $15.8 million
• Net profit after tax turned positive at $1.5 million
• Strong cash flow generation with $2.9 million in operating cash flow
• Successful completion of major MASH trial
• Record $12 million in SaMD orders and bids

Full summary

Resonance Health Ltd's FY26 results demonstrate significant growth and profitability. The company reported a 42% increase in revenue to $15.8 million, with a net profit after tax of $1.5 million, a significant improvement from the prior year's loss. Operating cash flow reached $2.9 million, and the company closed the year with $4.8 million in cash against $2.5 million of debt. The successful conclusion of the major MASH trial and a record $12 million in SaMD orders and bids highlight the company's strong performance and growth potential.

Guidance

Normalized EBITDA of $2.6 million, revenue of $15.8 million, net profit of $1.5 million

Outlook

Resonance Health aims to convert its $12 million SaMD orders and bids into contracted revenue, deliver the fibrosis study readout, and progress the liver fibrosis device toward investigational use in pharmaceutical trials.